HighTower Advisors LLC Sells 8,849 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

HighTower Advisors LLC trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,654 shares of the medical equipment provider's stock after selling 8,849 shares during the period. HighTower Advisors LLC's holdings in Zimmer Biomet were worth $5,667,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Dunhill Financial LLC increased its stake in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 218 shares during the period. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $25,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter worth approximately $35,000. Kentucky Trust Co bought a new position in Zimmer Biomet during the 4th quarter worth $39,000. Finally, OFI Invest Asset Management bought a new position in Zimmer Biomet during the 4th quarter worth $40,000. Institutional investors own 88.89% of the company's stock.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.95% of the company's stock.

Remove Ads

Zimmer Biomet Trading Down 0.9 %

ZBH traded down $0.99 during midday trading on Friday, hitting $110.79. 2,942,594 shares of the company were exchanged, compared to its average volume of 1,498,375. The firm has a market capitalization of $22.05 billion, a P/E ratio of 24.90, a P/E/G ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The firm's 50 day moving average price is $106.74 and its 200-day moving average price is $106.86. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm posted $2.20 EPS. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is presently 21.57%.

Analyst Ratings Changes

A number of research firms have commented on ZBH. Stifel Nicolaus raised their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. JMP Securities restated a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Royal Bank of Canada lowered their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research note on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.